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Endocrine therapy is the mainstay of treatment in
estrogen receptor-positive breast cancers and
significantly reduces disease recurrence and breast
cancer-related mortality. However, acquired resistance
to therapy has been noted in nearly one-third of
women treated with tamoxifen and other endocrine
therapies. Mutations in the estrogen receptor have
long been speculated to play a role in endocrine
therapy resistance but have been rarely detected.
However, recent studies utilizing next-generation
sequencing on estrogen receptor-positive, metastatic
clinical samples have revealed that recurrent ESR1
mutations are far more frequent than previously
thought and may play an important role in acquired
endocrine therapy resistance. Here we review recent
advances in detection and characterization of ESR1
mutations in advanced, endocrine therapy-resistant
breast cancers.that mediates specific recognition of ERE, a hinge do-Introduction
Acquired resistance to drug treatment is a major prob-
lem in cancer therapy. While many mechanisms of drug
resistance to chemotherapeutic agents such as efflux,
metabolism and inactivation have been described previ-
ously, alterations within the drug target have emerged as
a dominant resistance mechanism to targeted therapies
[1]. A classic example of such acquired resistance is gen-
omic amplification of the androgen receptor (AR) in
prostate cancer following treatment with AR antagonists
such as bicalutamide [2]. Other examples include ac-
quired mutations in the kinase domain of BCR-ABL1 in* Correspondence: arul@med.umich.edu
2Michigan Center for Translational Pathology, University of Michigan Medical
School, 1400 E. Medical Center Drive, 5316 CCC, Ann Arbor, MI 48109-5940,
USA
3Comprehensive Cancer Center, University of Michigan Medical School, 1400
E. Medical Center Drive, 5316 CCGC 5940, Ann Arbor, MI 48109-5940, USA
Full list of author information is available at the end of the article
© 2014 Alluri et al.; licensee BioMed Central Lt
months following its publication. After this tim
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/chronic myelogenous leukemia patients treated with
imatinib [3] and secondary mutations in epidermal
growth factor receptor in nonsmall-cell lung cancer pa-
tients treated with selective epidermal growth factor
receptor inhibitors such as gefitinib [4]. Target-related al-
terations that induce treatment resistance have also been
described in breast cancer. A mutated isoform of Her2
with truncation of the extracellular domain and constitu-
tive kinase activity has been shown to impair trastuzumab
binding and promote treatment resistance [5].
The estrogen receptor (ER) belongs to a family of nu-
clear hormone receptors that act as ligand-activated
transcription factors [6]. The binding of ligand induces a
conformational change in the receptor, which translo-
cates to the nucleus, binds as a homodimer to specific
DNA sequences termed estrogen response elements
(ERE) and regulates the transcription of multiple target
genes. The domain architecture of the ER includes an
N-terminal hormone-independent transactivation do-
main (AF1), a highly conserved DNA-binding domain
main that separates the DNA-binding domain from the
ligand-binding domain (LBD), a LBD that contains the
hormone binding pocket, and a second transactivation
domain (AF2) in the C-terminus that is activated in re-
sponse to ligand binding [7]. The etiological role of
estrogens in breast cancer is well established and modu-
lation of estrogen signaling remains the mainstay of
breast cancer treatment for the majority of breast can-
cers classified as ER-positive [8]. Several strategies for
inhibiting the estrogen axis in breast cancer exist, in-
cluding: selective ER modulators such as tamoxifen and
raloxifene, which act as selective tissue-specific antago-
nists of ER in the breast [9]; selective ER degraders such
as fulvestrant, which promote ER turnover [10]; and aro-
matase inhibitors such as exemestane (steroidal aroma-
tase inhibitors), anastazole and letrazole (nonsteroidal
aromatase inhibitors) – agents primarily used in post-
menopausal women with ER-positive breast cancer –
which inhibit estrogen biosynthesis [11].d. The licensee has exclusive rights to distribute this article, in any medium, for 6
e, the article is available under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Alluri et al. Breast Cancer Research 2014, 16:494 Page 2 of 8
http://breast-cancer-research.com/content/16/6/494While endocrine therapy has contributed significantly
to reduction in disease development, recurrence and
breast cancer-related deaths, one-third of women treated
with tamoxifen for 5 years have been reported to have
recurrent disease within 15 years [12]. Acquired endo-
crine therapy-resistant disease has thus been estimated
to develop in up to one-quarter of all breast cancers
[13]. Intense efforts are therefore focused on studying
the underlying molecular mechanisms that contribute to
endocrine therapy resistance. Multiple growth factor re-
ceptor signaling pathways have been implicated in the
development of endocrine therapy resistance, including
human epidermal growth factor 2, mitogen-activated pro-
tein kinase, phosphoinositide 3-kinase/mammalian target
of rapamycin, insulin-like growth factor 1 receptor and
fibroblast growth factor receptor signaling pathways [14].
It has been speculated for many years that acquired mu-
tations in ER which occur after initiation of hormone
therapy may play a role in treatment failure and disease
progression. Sluyser and Mester proposed that certain
mutations in steroid receptors may result in their ability
to bind to DNA in the absence of ligand and may confer
hormone independence in cells harboring such mutant
receptors [15]. However, reports of acquired mutations
in the ER itself have been sparse despite persistent ef-
forts to identify such mutations [16-19].
In one of the first reports of acquired ESR1 mutations in
human breast cancers, Fuqua and coworkers in 1997 de-
scribed a nonsynonymous mutation in Tyr537 (Y537N) in
a study of 30 metastatic breast cancer tumors and impli-
cated this mutation in hormone-independent constitutive
activation of the ER [18]. Subsequent studies failed to
validate this finding, however, probably because most of
these studies focused on primary breast tumors instead
of metastatic lesions and employed techniques that had
low sensitivity for detecting rare mutations in the back-
ground of the wild-type alleles. The advent of more sophis-
ticated and sensitive technologies such as next-generation
sequencing has aided the search for genomic alterations in
ER in response to endocrine therapy, and recent discover-
ies have renewed interest in ESR1 mutations as a potential
mechanism of endocrine therapy resistance [20].
Estrogen receptor mutations in breast cancer
Recently, we initiated the clinical sequencing program
MI-ONCOSEQ (The Michigan Oncology Sequencing
Program) to identify potential actionable genomic alter-
ations in various cancers [21]. As a part of this program,
we performed integrative sequencing on 11 metastatic
ER-positive breast cancer patients including whole-exome
sequencing of the tumor and matched normal tissue, tran-
scriptome sequencing and low-pass whole-genome sequen-
cing, as needed. In addition to several potentially actionable
aberrations, we noted nonsynonymous mutations in ESR1in six of the 11 patients (ER L536Q in one patient, D538G
in two patients and Y537S in three patients) [22]. Interest-
ingly, all mutations localized to the LBD of the ER. Further-
more, all of the index patients had a history of treatment
with anti-estrogens (tamoxifen and/or fulvestrant) and aro-
matase inhibitors. More significantly, when clinical sequen-
cing was performed on pretreatment primary diagnostic
tissue from three of the patients for whom the material was
available, these mutations were not detected – suggesting
that the mutations were acquired following initiation of
endocrine therapy. Consistent with this observation, no
ESR1 mutation was found in the pretreatment, primary
resection tissue of 390 ER-positive breast carcinoma
patients from The Cancer Genome Atlas study [23] or
in our cohort of 80 triple-negative breast carcinoma
transcriptomes. Similarly, a whole-genome sequencing
study of 46 ER-positive, pretreatment breast cancer
samples from two neoadjuvant aromatase inhibitor
therapy trials [ClinicalTrials.gov:NCT00084396, Clini-
calTrials.gov:NCT00265759] did not reveal any ESR1
mutations [24]. Interestingly, somatic mutations in the
LBD of the ER (Y537C and Y537N) were also detected
in four of 373 cases of endometrial cancer in The Cancer
Genome Atlas database [25]. It is not known whether
these patients have a history of endocrine therapy, al-
though it is tempting to speculate that these mutations
arose in patients who had concurrent breast cancer, as
these patients often are treated with tamoxifen (which is a
known risk factor for endometrial cancer) and estrogen
deprivation therapy [26].
Our findings of acquired ESR1 mutations in meta-
static, endocrine therapy-resistant breast cancers have
been independently corroborated by other groups and
have been described previously by Li and colleagues in
ER-positive xenografts derived from poor-prognosis,
treatment-resistant tumors [27]. In a targeted approach
aimed at understanding the genetic basis for acquired
hormonal therapy resistance in ER-positive breast can-
cers, Toy and coworkers surveyed mutations and copy
number alterations in 230 commonly mutated genes of
tumors from metastatic ER-positive breast cancer patients
[28]. The authors found ESR1 mutations in seven out of
22 tumors that had matched normal DNA and in an add-
itional two out of 14 tumors that did not have matched
normal DNA (for a total of 9/36 cases sequenced). All of
the patients had been on hormonal therapy for at least
3 months (and an average of 4.9 years) but experienced
disease progression while on therapy. Treatment-naïve
primary tumor samples were available from two of the
nine patients with ESR1 mutations and no ESR1 muta-
tions were found in the primary tumor.
To further validate these findings, the authors ana-
lyzed primary tumors as well as a subset of metastatic
tumors collected after hormonal therapy from patients
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that ESR1 mutations were present in only 6/183 (3%)
primary tumors but in 5/44 (11%) metastatic tumors.
The higher rate of ESR1 mutations in primary tumors
(3%) in this study is probably related to the fact that pa-
tients enrolled in the BOLERO-2 clinical trial had ad-
vanced breast cancer and had disease progression or
recurrence after treatment with an aromatase inhibitor
(letrozole or anastrozole). The ESR1 mutations in these
primary tumors thus probably arose in response to es-
trogen deprivation. In contrast, nearly all studies on
treatment-naïve, primary breast tumors showed no evi-
dence of ESR1 mutations. Remarkably, all mutations in
ESR1 in this study also clustered in the same region in
the LBD and showed a high degree of overlap to the
mutations described in our study, and included V534E,
P535H, L536R, Y537C, Y537N, Y537S, D538G, S463P/
Y537N, S463P/D538G and Y537S/D538G, suggesting
that the selective pressure of estrogen deprivation en-
riches for activating mutations in the LBD of ESR1.
In a study of genomic profiling of 249 (134 ER-positive
and 115 ER-negative) tumor specimens from 208 patients,
Jeselsohn and colleagues carried out DNA sequencing of
3,230 exons of 182 cancer-related genes and 37 introns of
14 commonly fused genes, including in 37 pairs of
matched primary and metastatic breast tumors [30].
Consistent with previous studies, two ER mutations
(Y537C and D538G) were reported in this study in
metastatic tumors but not in the matched primary tu-
mors. In another metastatic lesion harboring the ER
Y537C mutation, the authors were able to sequence tis-
sue from the same metastatic site at two different time
points. The initial biopsy obtained before initiation of
tamoxifen did not show the mutation while a subse-
quent biopsy from the same site after 8 years of treat-
ment did. Overall, 16 ESR1 point mutations were found
across 249 specimens and 12 of those were assessed to
be somatic in nature. However, the lack of matched nor-
mal specimens in this study made it difficult to make
definitive determination of the somatic status of the ob-
served mutations. When the authors focused on previ-
ously described codon 537/538 mutations in ESR1, they
found them in nine of 76 (12%) metastatic, ER-positive
tumors and in zero of 58 primary ER-positive and zero
of 115 ER-negative tumors. Furthermore, the mutation
rate was even higher (20%) in heavily pretreated meta-
static patients, who on average had received seven lines
of previous treatment, including at least two endocrine
treatments.
In another study that included 13 tumor samples from
Israeli patients with metastatic, ER-positive breast cancer
who failed multiple treatments, Merenbakh-Lamin and
coworkers performed commercially available genetic
analysis by next-generation sequencing of 182 cancer-related genes on DNA extracted from formalin-fixed
paraffin-embedded tissue samples and reported ER
D538G mutation in five patients (38%) [31]. Interest-
ingly, the biopsies harboring this mutation originated
from liver metastases in all of the patients and all pa-
tients who tested positive for the mutation had received
at least two lines of endocrine therapy for a minimum of
5 years prior to onset of endocrine resistance. Consistent
with other studies, the primary tumors did not harbor
any mutations in ESR1.
In a study aimed at genomic characterization of endo-
crine therapy-resistant ESR1 variants in patient-derived
xenografts (PDX), Li and colleagues evaluated ER-positive
xenografts derived from poor-prognosis, treatment-
resistant tumors by monitoring their growth after trans-
plantation into oophorectomized mice [27]. Among six
PDX evaluated, only one exhibited estradiol-dependent
growth while four demonstrated estradiol-independent
growth. The growth of the remaining xenograft was
inhibited by estradiol, consistent with paradoxical re-
sponse of some advanced breast cancers to estradiol.
The authors employed RNA-seq analysis of the PDX
and identified genomic alterations in four of the xeno-
grafts. One alteration included an ESR1/YAP1 fusion in-
volving the first four exons of the ER (amino acids 1 to
365) and the C terminus of YAP1 (amino acids 230 to
504). Another alteration involved ESR1 gene amplifica-
tion with associated high protein levels, with the other
two alterations involving mutational events (an ER
Y537S mutation and an E380Q mutation).
The discovery of recurrent ESR1 mutations in endo-
crine therapy-resistant, metastatic breast cancer spurred
interest in functional characterization of these genetic al-
terations. In our study, we evaluated the response of
ESR1 mutations to estradiol and anti-estrogens in an
ERE–luciferase reporter assay system [22]. Interestingly,
all ESR1 mutants showed robust constitutive activation
of the ERE reporter, unlike the wild-type ESR1 that had
little activity in the absence of estradiol. The ESR1 mu-
tants did not show significant further increase in ERE re-
porter activity following stimulation with estradiol.
Interestingly, all of the mutants identified in our study
showed a dose-dependent inhibitory response to tamo-
xifen and fulvestrant. These findings argue that the ER
mutants arose under selective pressure from estrogen
deprivation therapy rather than from anti-estrogen ther-
apy. However, the ESR1 mutants showed a slightly blunted
response to both 4-hydroxytamoxifen and fulvestrant with
a twofold to fourfold increase in half-maximal inhibitory
concentration values. Similar high constitutive activation
of ESR1 mutants (except S463P) with concomitant in-
crease in the transcript levels of estrogen-responsive genes
such as GREB1, MYC, PGR and TFF1 and reduced, but
retained, response to anti-estrogens was noted by Toy and
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cells in hormone-depleted medium was performed follow-
ing transfection with the mutant ESR1 constructs with the
highest constitutive activity (Y537S, D538G and S463P/
D538G), the mutants demonstrated a unique and shared
gene expression pattern that was distinct from the wild-
type receptor. These mutants also demonstrated an ele-
vated level of phosphorylation of Ser118 in the AF-1
domain, a post-translational modification previously
implicated in increased ligand-independent activity of
the ER. The D538G mutant also demonstrated in-
creased interaction with coactivator protein A1B1 when
compared with the wild-type protein. These findings
were further corroborated by Jeselsohn and colleagues,
who also reported constitutive activation of D538G mu-
tant ER in reporter gene assays and increased ligand-
independent interaction of ESR1 D538G mutant with
SRC-1, when compared with the wild-type receptor
[30]. Furthermore, the D538G mutant demonstrated in-
creased proliferation and migration in MTT and wound
healing assays, respectively, compared with the wild-
type protein. Additionally, the ESR1 mutants discovered
in the Li and colleagues xenograft study have also been
functionally characterized and both ESR1/YAP1 and ER
Y537S mutants showed increased constitutive activa-
tion and proliferation in low-estrogen conditions [27].
Finally, when stable MCF7 cell lines with ectopic ex-
pression of wild-type, Y537S and D538G mutants were
used to establish tumors in nude mice, cells harboring
the mutant protein had dramatically increased tumor
growth compared with wild-type cells [28]. These find-
ings suggest that mutant ER proteins afforded signifi-
cant growth advantage to the breast cancer cells.
Interestingly, the structural and functional charac-
terization of Tyr537 mutations preceded their discovery
in human cancers. Since Tyr537 resides in close pro-
ximity to the region of the ER that is important for
ligand-dependent transcriptional function, extensive
mutational studies have been carried out to probe its
function in estrogen signaling. For instance, Weis and
coworkers carried out site-directed mutagenesis of the
ER and substituted Y537 with five differing amino acids
(alanine, phenylalanine, glutamic acid, lysine and
serine), noting that Y537S displayed the highest consti-
tutive activity and was indistinguishable from wild-type
ER activity in the presence of estradiol [32]. Further-
more, the extent of the constitutive activity of the
mutant receptors strongly correlated with their ability
to interact with SRC-1, a known ER coactivator. The
Y537S mutant, which showed full constitutive activity
in the absence of estradiol, was thus also capable of
maximal interaction with SRC-1 in the complete ab-
sence of estradiol. Moreover, the interaction with SRC-
1 was blocked by anti-estrogens, consistent withfindings that these mutant receptors retained sensitivity
to tamoxifen and fulvestrant. This study suggested that
certain ER mutations may facilitate shift of helix 12 of
ESR1 into a conformation that mimics the ligand-
bound active state of the receptor [33]. In fact, struc-
tural studies of Y537S mutant by X-ray crystallography
have provided evidence for such a conformational
change. Nettles and colleagues crystallized the Y537S
mutant protein, in complex with an NR box II peptide
from the coactivator protein GRIP1, and demonstrated
that the mutant protein exists in the canonical agonist
conformation with helix 12 folded across helix 3 and
helix 11 [34]. Moreover, the mutant Y537S apostructure
showed a high degree of similarity to wild-type ER
bound to diethylstilbesterol [35], a full ER agonist, con-
firming that the Y537S mutant mimics the ligand-
occupied, active ER conformation.
These studies have shown that Tyr537 hydrogen bonds
with Asn348 in the wild-type receptor, resulting in
stabilization of the backbone of the helix 11–12 loop
and leaving Leu536 in a solvent-exposed position. How-
ever, in the Y537S mutant, Ser537 has been shown to es-
tablish a hydrogen-bonding interaction with Asp351
resulting in an altered conformation of the helix 11–12
loop and burial of Leu536 in a solvent-inaccessible pos-
ition. This has been postulated to contribute to constitu-
tive activity of the Y537S mutant protein. Interestingly,
the Y537S surface mutation has been shown to have no
impact on the structure of the LBD pocket, an observation
consistent with functional studies that demonstrated
retained sensitivity to anti-estrogens [22,28]. These struc-
tural studies also support the notion that ESR1 mutations
probably arose in response to an estrogen-deprived state
rather than anti-estrogen therapy [22].
While an X-ray crystal structure of D538G mutant
protein has not been reported in the literature, extensive
structural modeling studies have been reported previ-
ously [28,31]. When molecular dynamics simulation
studies of the wild-type and D538G mutant proteins
were performed in the absence of ligand and bound to a
coactivator protein, TIF2, a hydrogen-bonding inter-
action was noted between the backbone of Gly538 and
the side chain of Asp351 that resulted in shifting of
G538 towards helix H3 in the mutant receptor that was
not present in the wild-type protein [28]. It has been
postulated that the Gly538–Asp531 hydrogen bond was
enabled by the flexibility of glycine residue owing to its
small size, which allows it to adopt backbone conforma-
tions that are not accessible for other amino acids. This
results in a conformation of the mutant receptor that is
similar to the estrogen-bound wild-type receptor and ex-
plains its constitutive activity. The structural basis for
constitutive activity of other mutant ER proteins is less
well understood although biochemical characterization
Figure 1 Evolution of ESR1 mutations in estrogen receptor-
positive breast cancer with endocrine therapy treatment. ESR1
mutations are rare or nonexistent in primary breast tumors and are
significantly enriched in metastatic, endocrine therapy-resistant breast
cancer. Nearly all ESR1 mutations localize to the ligand-binding domain
(LBD) of the estrogen receptor (ER) and often result in constitutive
activation of the ER. DBD, DNA-binding domain.
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[36-39].
Conclusion
In summary, ESR1 mutations are significantly enriched
in endocrine therapy-resistant, metastatic breast cancer
and are rare or nonexistent in treatment-naïve, primary
tumors (Figure 1). Based on published reports, the over-
all frequency of ER mutations in metastatic, ER-positive
breast cancers ranged from 11 to 54.5%, depending on
the clinical characteristics of the cohort and the method
of identification [22,28,30,31]. Larger prospective studies
with standardized detection methods may be needed to
establish the true incidence of these mutations. While
the evolution of these mutations appears to be strongly
correlated with endocrine therapy resistance, a causal
relationship between ESR1 mutations and endocrine
therapy resistance remains to be established. We have,
however, noted significant upregulation of ER-responsive
genes such as GREB1 in tumors harboring ESR1 muta-
tions, suggesting that ER signaling is active in these tu-
mors and may play a role in conferring endocrine
therapy resistance (DR Robinson, AM Chinnaiyan, et al.,
unpublished data).
Future prospective studies involving long-term moni-
toring of patients undergoing endocrine therapy by less
invasive methods such as circulating tumor cells may be
necessary to establish the evolutionary timeline of these
mutations and their relationship to development of endo-
crine therapy resistance. Indeed, recent technical advances
in single-cell sequencing capability may make future
monitoring of ESR1 mutations in patients receiving
endocrine therapy feasible [40]. It remains to be seen
whether early detection and intervention, either by a
change in endocrine therapy or by addition of other
agents, will result in a clinically meaningful improve-
ment in outcomes. In theory, while detection of ESR1
mutations may prompt a clinician to change the treat-
ment regimen from, say, an aromatase inhibitor to an
anti-estrogen, it is already known that patients who de-
velop resistance to aromatase inhibitors often respond
to anti-estrogen therapy [41]. Such a change in treat-
ment regimen is thus likely to happen even in the ab-
sence of information on ESR1 mutation status. Whether
preemptive changes to the treatment regimen in re-
sponse to early detection of ESR1 mutation(s) and prior
to onset of clinically detectable disease progression im-
pacts clinical outcomes is an open question and may
need to be addressed in a prospective study. Further-
more, the contribution of other genomic and nonge-
nomic alterations that coevolve with ESR1 mutations
also needs to be determined and merits further investi-
gation. Finally, the prognostic significance of ESR1 mu-
tations in predicting clinical outcomes among patients
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area of great clinical interest.
While numerous unknowns remain regarding the role of
ESR1 mutations in advanced, endocrine therapy-resistant
breast cancer, their identification certainly opens exciting
new avenues of research that will deepen our knowledge
and understanding of the molecular basis for acquired
endocrine therapy resistance. It is quite remarkable that a
very limited number of residues in the LBD of the ER
serve as hotspots for evolution of endocrine therapy
resistance. It is gratifying that multiple laboratories
studying diverse patient populations with advanced,
treatment-resistant breast cancer have verified ESR1 muta-
tions, thus validating those who suggested their existence
nearly 30 years ago [15]. These findings have the potential
for providing a framework for understanding the struc-
tural determinants of ER that contribute to endocrine
therapy resistance and coupling them with genomic alter-
ations that evolve in response to therapy.
Furthermore, the retained sensitivity but decreased effi-
cacy of anti-estrogens in preclinical ESR1 mutant models
suggests that the standard dose of anti-estrogens such as
tamoxifen often used in the aromatase inhibitor-refractory
setting may be inadequate in ESR1 mutant breast cancers.
Prospective clinical trials evaluating the benefits of dose
escalation of anti-estrogens such as tamoxifen and fulves-
trant may therefore be warranted in ESR1 mutant breast
cancers that have failed standard-dose anti-estrogen ther-
apy. Detailed structural studies on mutant ER proteins
may also open the door for development of more potent
and mutant-specific ER antagonists and selective ER de-
graders. Finally, while studies have demonstrated that cer-
tain ESR1 mutations may result in increased interaction
with known ER coactivators such as SRC-1 in a ligand-
independent fashion, it is unclear whether ESR1 mutations
alter the interactome of the ER. Such studies may uncover
novel protein interactions with mutant ERs that may be
amenable to therapeutic targeting. In this regard, develop-
ment of reliable preclinical models of endocrine therapy
resistance in the background of ESR1 mutations would be
highly valuable. Encouragingly, the most common ESR1
mutation (Y537S) in our study as well as in the Chandar-
lapaty study has independently evolved in PDX grown
under low estrogen conditions [27]. It would be interesting
to see whether the other ESR1 alterations detected in the
PDX will eventually be found in patient samples. A high
concordance between ESR1 mutations that evolved in
PDX and human tumors bolsters our confidence in
using PDX as a reliable model for evaluating novel
therapeutic strategies for treatment of endocrine ther-
apy resistance that evolved in the background of ESR1
mutations.
Finally, alterations in the ER that contribute to en-
docrine therapy resistance provide opportunities fortargeting pathways downstream of the ER activation.
Recently, we have shown that bromodomain proteins
such as BRD4 physically interact with the AR and are
necessary for AR-mediated transcription in metastatic
castration-resistant prostate cancer models. We have
also demonstrated that bromodomain inhibitors such
as JQ1 are more efficacious than direct AR antagonism in
treatment of castration-resistant prostate cancer in mouse
models [42]. These observations provide a further frame-
work for identifying novel effectors of mutant ERs that
may serve as attractive targets for therapeutic intervention
in advanced, endocrine therapy-resistant breast cancers.
The recent discovery of recurrent ESR1 mutations in
metastatic ER-positive breast cancers may merely repre-
sent the tip of the iceberg but do provide the basis for
further exploration of endocrine therapy resistance mecha-
nisms and the next generation of targeted therapies.
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